Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain

This study has been terminated.
(Difficulty identifying and enrolling eligible patients)
Sponsor:
Information provided by (Responsible Party):
ZARS Pharma Inc.
ClinicalTrials.gov Identifier:
NCT00278824
First received: January 16, 2006
Last updated: June 4, 2012
Last verified: June 2012

January 16, 2006
June 4, 2012
January 2006
August 2006   (final data collection date for primary outcome measure)
Patient's rating of pain intensity (NRS), the patient's evaluation of pain relief using a 5-point verbal rating scale (VRS), and the patient's global satisfaction assessment. [ Time Frame: 0, 15, 20, 60 minutes ] [ Designated as safety issue: No ]
Efficacy will be evaluated by the patient's rating of pain intensity using an 11-point numerical rating scale (NRS), the patient's evaluation of pain relief using a 5-point verbal rating scale (VRS), and the patient's global satisfaction assessment.
Efficacy will be evaluated by the patient’s rating of pain intensity using an 11-point numerical rating scale (NRS), the patient's evaluation of pain relief using a 5-point verbal rating scale (VRS), and the patient's global satisfaction assessment.
Complete list of historical versions of study NCT00278824 on ClinicalTrials.gov Archive Site
  • Adhesion assessment [ Time Frame: 3 days ] [ Designated as safety issue: Yes ]
    An adhesion assessment will be conducted by the patient at each CHADD removal.
  • Pain Relief [ Time Frame: 15, 30, 60 minutes ] [ Designated as safety issue: No ]
    Patient's evaluation of pain relief using a 5-point verbal rating scale (VRS)
  • Patient's Global Satisfaction Assessment [ Time Frame: 60 minutes ] [ Designated as safety issue: No ]

    Patients completed a global satisfaction assessment 60 minutes after CHADD application. Patients were asked to assess their overall satisfaction with the CHADD throughout the 60 minute application period for the treatment of their breakthrough pain using the following 5-point scale: 0=not satisfied,

    1=somewhat satisfied, 2=moderately satisfied, 3=very satisfied, and 4=completely satisfied.

  • Number of participants with adverse events [ Time Frame: 15 days ] [ Designated as safety issue: Yes ]
    The frequency of adverse events, severity, and relationship to study drug was recorded.
An adhesion assessment will be conducted by the patient at each CHADD removal.
Not Provided
Not Provided
 
Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain
A Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy of CHADD™ Applied Over a Transdermal Fentanyl Patch for the Treatment of Breakthrough Pain in Patients With Moderate to Severe Non-malignant Chronic Pain

A multi-center study to evaluate the efficacy of CHADD (Controlled Heat-Assisted Drug Delivery) applied over a 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch for the treatment of breakthrough pain in adult patients with moderate to severe non-malignant chronic pain. The open-label study arm will last up to 12 days. The double-blind arm will last up to 15 days. Eligible patients who complete the open-label arm will be allowed to enroll in the double-blind study arm.

ZARS Pharma is developing a Matrix Transdermal Fentanyl/CHADD (Controlled Heat-Assisted Drug Delivery) Drug Delivery System to be used for the treatment of chronic and breakthrough pain. The Matrix Transdermal Fentanyl/CHADD Drug Delivery System has been designed to provide long-term delivery of fentanyl for the treatment of chronic pain as well as intermittent increases in fentanyl concentrations for the treatment of breakthrough pain. Breakthrough pain is defined as a transitory exacerbation of pain that occurs on a background of otherwise stable pain in a patient receiving chronic opioid therapy.

Matrix Transdermal Fentanyl/CHADD Drug Delivery System has 2 components: a matrix transdermal fentanyl patch (the ZR-02-01 patch in doses of 25, 50, 75 and 100 mcg/hr) with corresponding thin film dressing (ie, overlay) and the CHADD (Controlled Heat-Assisted Drug Delivery).

The matrix transdermal fentanyl patch provides a continuous delivery of fentanyl over 72 hours, in a manner similar to Duragesic®. During a breakthrough pain episode, a CHADD unit is placed over (adhered to) the matrix transdermal fentanyl patch. The CHADD is a thin patch-like chemical heating device that generates a controlled level of heat for approximately 15-20 minutes. The application of heat delivers increased amounts of fentanyl when applied over the ZR-02-01 matrix transdermal fentanyl patch.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Pain
  • Drug: Matrix Transdermal Fentanyl/CHADD Drug Delivery System
    Patch applied every 3 days for 15 days
    Other Names:
    • ZR-02-01
    • Fentanyl Transdermal Matrix Patch
  • Drug: Placebo Patch
    Placebo patch applied every 3 days for 15 days
    Other Name: Placebo Matrix Patch
  • Experimental: 50 mcg/hr matrix fentanyl patch
    active 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch (20 cm2)
    Intervention: Drug: Matrix Transdermal Fentanyl/CHADD Drug Delivery System
  • Placebo Comparator: Placebo Patch
    placebo (20 cm2) will be indistinguishable in size, shape, and appearance to the active matrix fentanyl patch
    Intervention: Drug: Placebo Patch
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
109
August 2006
August 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient is 18 through 70 years of age.
  • Patient has moderate to severe non-malignant chronic pain.
  • Patient is opioid-tolerant, requires treatment with chronic opioids and is currently taking a dose of 50 mcg/hr transdermal fentanyl for the treatment of chronic pain. Patient must have been taking this dose for at least 2 weeks.
  • Patient must be experiencing 1 to 4 episodes of target breakthrough pain (breakthrough pain that is related to the patient's chronic pain condition) a day while taking a dose of 50 mcg/hr transdermal fentanyl.

Exclusion Criteria:

  • Patient has active cancer.
  • Patient has a history of substance abuse or has a substance abuse disorder.
  • Patient is pregnant or breastfeeding.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00278824
ZCM-201
No
ZARS Pharma Inc.
ZARS Pharma Inc.
Not Provided
Principal Investigator: Lynn R Webster, MD Lifetree Clinical Research
ZARS Pharma Inc.
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP